Thalidomide combined with irradiation alters the activity of two proteases

Şimşek,Ece; Aydemir,Esra; Korcum,Aylin  Fidan; Fişkın,Kayahan

doi:10.3892/mmr.2014.2831

Thalidomide combined with irradiation alters the activity of two proteases

Authors:
- Ece Şimşek
- Esra Aydemir
- Aylin Fidan Korcum
- Kayahan Fişkın
View Affiliations

Affiliations: Department of Nutrition and Dietetics, Akdeniz University, Antalya School of Health, Antalya 07058, Turkey, Department of Biology, Akdeniz University, Science Faculty, Antalya 07058, Turkey, Department of Radiation Oncology, Akdeniz University, Medicine Faculty, Antalya 07058, Turkey
Published online on: October 31, 2014 https://doi.org/10.3892/mmr.2014.2831
Pages: 1535-1541

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of thalidomide, a drug known for its anti‑angiogenic and antitumor properties, at its cytotoxic dose previously determined as 40 µg/ml (according to four cytotoxic test results). The effect of the drug alone and in combination with radiotherapy using Cobalt 60 (60Co) at 45 Gy on the enzymatic activity of substance‑P degrading A disintegrin and metalloproteinase (ADAM)10 and neprilysin (NEP) was investigated in the mouse breast cancer cell lines 4T1 and 4T1 heart metastases post‑capsaicin (4THMpc). Thalidomide (40 µg/ml) exerted differing effects on the activities of ADAM10 and NEP enzymes. In 4T1 cells, 40 µg/ml thalidomide alone did not alter ADAM10 enzyme activity. 60Co irradiation at 45 Gy alone caused a 42% inhibition in ADAM10 activity, however, the inhibition increased to 89% when combined therapy was used. By contrast, in the 4THMpc cell line, 40 µg/ml thalidomide alone induced a 66.6% increase in ADAM10 enzyme activity. Radiotherapy alone and thalidomide with 60Co combined therapy caused a 33.3 and 40% inhibition of ADAM10 activity, respectively. In 4T1 cells, thalidomide alone caused a 40.9% increase in NEP activity. Radiation therapy alone or in combination with the drug caused a 40.7% increase in NEP activity. In more aggressive 4THMpc cells, thalidomide alone caused a 26.6% increase in NEP activity. Radiotherapy alone and combined therapy caused a 33.3 and 37% increase in enzyme activity, respectively. To the best of our knowledge, the present study is the first to demonstrate that thalidomide alone or in combination with radiotherapy exhibits significant cytotoxic effects on 4T1 and 4THMpc mouse breast cancer cell lines indicating that this drug affects the enzymatic activity of ADAM10 and NEP in vitro.

View Figures

View References

1	Papaiakovou VE, Bamias A and Dimopoulos MA: Thalidomide in cancer medicine. Ann Oncol. 15:1151–1160. 2004. View Article : Google Scholar
2	D’Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar
3	Kenyon BM, Browne F and D’Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 64:971–978. 1997. View Article : Google Scholar : PubMed/NCBI
4	Bauer KS, Dixon SC and Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 55:1827–1834. 1998. View Article : Google Scholar : PubMed/NCBI
5	Majumdar S, Lamothe B and Aggarwal BB: Thalidomide suppresses NF-κB activation induced by TNF and H₂O₂, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol. 168:2644–2651. 2002. View Article : Google Scholar : PubMed/NCBI
6	Macpherson GR, Franks M, Tomoaia-Cotisel A, et al: Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol. 46:49–57. 2003. View Article : Google Scholar
7	Eichhorn ME, Kleespies A, Angele MK, et al: Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg. 392:371–379. 2007. View Article : Google Scholar : PubMed/NCBI
8	Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58–61. 1989. View Article : Google Scholar : PubMed/NCBI
9	Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
10	Huang Z and Bao SD: Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol. 10:463–470. 2004.PubMed/NCBI
11	Eichhorn ME, Strieth S and Dellian M: Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat. 7:125–138. 2004. View Article : Google Scholar : PubMed/NCBI
12	Rajkumar SV: Current status of thalidomide in the treatment of cancer. Oncology (Williston Park). 15:867–874. 2001.
13	Sumner SC, Gallagher KS and Davis DG: Conformational analysis of the tachykinins in solution: substance P and physalaemin. J Biomol Struct Dyn. 8:687–707. 1990. View Article : Google Scholar : PubMed/NCBI
14	Carter MS and Krause JE: Structure, expression and some regulatory mechanisms of the rat preprotachykinin gene encoding substance p, neurokinin a, neuropeptide k, and neuropeptide gamma. J Neurosci. 10:2203–2214. 1990.PubMed/NCBI
15	Erin N and Ulusoy O: Differentiation of neuronal from non-neuronal Substance P. Regul pept. 152:108–113. 2009. View Article : Google Scholar
16	Harrison S and Geppetti P: Substance p. Int J Biochem Cell Biol. 33:555–576. 2001. View Article : Google Scholar : PubMed/NCBI
17	Erin N, Zhao W, Bylander J, et al: Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat. 99:351–364. 2006. View Article : Google Scholar : PubMed/NCBI
18	Erin N, Boyer PJ, Bonneau RH, et al: Capsaicin-mediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res. 24:1003–1009. 2004.PubMed/NCBI
19	Harrison LB, Chadha M, Hill RJ, et al: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 7:492–508. 2002. View Article : Google Scholar : PubMed/NCBI
20	Rampling R, Cruickshank G, Lewis AD, et al: Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phy. 29:427–431. 1994. View Article : Google Scholar
21	Lartigau E, Randrianarivelo H, Avril MF, et al: Intratumoral oxygen tension in metastatic melanoma. Melanoma Res. 7:400–406. 1997. View Article : Google Scholar
22	Nordsmark M, Hoyer M, Keller J, et al: The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 35:701–708. 1996. View Article : Google Scholar : PubMed/NCBI
23	Movsas B, Chapman JD, Greenberg RE, et al: Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer. 89:2018–2024. 2000. View Article : Google Scholar : PubMed/NCBI
24	Mundt AJ, Connell PP, Campbell T, et al: Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol. 71:151–158. 1998. View Article : Google Scholar : PubMed/NCBI
25	Vaupel P, Briest S and Höckel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wein Med Wochenschr. 152:334–342. 2002. View Article : Google Scholar
26	Harrison L and Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 9:31–40. 2004. View Article : Google Scholar : PubMed/NCBI
27	Oz ES, Aydemir E, Korcum AF and Fiskin K: Thalidomide and irradiation combination therapy increases substance P levels in vitro. Exp Ther Med. 2:529–535. 2011.PubMed/NCBI
28	D’Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar
29	Bartlett JB, Dredge K and Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 4:314–322. 2004. View Article : Google Scholar : PubMed/NCBI
30	Downs LS Jr, Rogers LM, Yokoyama Y and Ramakrishnan S: Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer. Gynecol Oncol. 98:203–210. 2005. View Article : Google Scholar : PubMed/NCBI
31	Vandeputte-Rutten L and Gros P: Novel proteases: common themes and surprising features. Curr Opin Struc Biol. 12:704–708. 2002. View Article : Google Scholar
32	Chubinskaya S, Mikhail R, Deutsch A and Tindal MH: ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound from and is upregulated in osteoarthrits and in response to IL-1 alpha in bovine nasal cartilage. J Histochem Cytochem. 49:1165–1176. 2001. View Article : Google Scholar : PubMed/NCBI
33	Turner AJ and Hooper NM: The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci. 23:177–183. 2002. View Article : Google Scholar : PubMed/NCBI
34	Shipp MA, Richardson NE, Sayre PH, et al: Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci USA. 85:4819–4823. 1988. View Article : Google Scholar : PubMed/NCBI
35	Luo W, Sharif TR and Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogenactivated protein kinase signaling pathway. Cancer Res. 56:4983–4991. 1996.PubMed/NCBI
36	Defea KA, Zalevsky J, Thoma MS, et al: Beta arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 148:1267–1281. 2000. View Article : Google Scholar : PubMed/NCBI
37	Bhatia M, Saluja AK, Hofbauer B, Frossard JL, Lee HS, Castagliuolo I, Wang CC, Gerard N, Pothoulakis C and Steer ML: Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci USA. 95:4760–4765. 1998. View Article : Google Scholar : PubMed/NCBI
38	Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, et al: Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 73:6424–6434. 2013. View Article : Google Scholar : PubMed/NCBI
39	Muñoz M and Coveñas R: Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med. 10:305–313. 2010.PubMed/NCBI
40	Esteban F, Muñoz M, González-Moles MA and Rosso M: A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 25:137–145. 2006. View Article : Google Scholar : PubMed/NCBI